Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2015

Epiduo Forte(Adapalene/Benzoyl Peroxide)

Medicare prescription drug cost, prescriptions and prescribers, 2024

$61K

Medicare cost, 2024

Medicare drug plans spent $60,855 on Epiduo Forte (adapalene/benzoyl peroxide) in 2024, for 87 prescriptions and refills filled by 36 patients. Spending fell 21% from 2023 to 2024.

Medicare cost, 2024

$61K

-20.9% from 2023

Prescriptions

87

$699.48 per claim

Patients

36

39 prescribers

Total spending, 2024

$61K

$1,690.42 per patient

Questions and answers

How much does Medicare spend on Epiduo Forte?

Medicare prescription drug plans paid $61K for Epiduo Forte in 2024, for 87 prescriptions and refills to 36 patients (down 20.9% from 2023). The average cost per claim was $699.48.

Which state spends the most on Epiduo Forte?

Maryland had the highest Medicare cost for Epiduo Forte in 2024: $9,468 for 13 claims, followed by Pennsylvania ($7,019).

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Epiduo Forte was $61K in 2024, after a high of $473K in 2021.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Prescriber data by year

YearPrescribersClaimsPatientsCost
202210124197$150K
20235412350$77K
2024398736$61K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Galderma Labora87$61K

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
8
RxNorm concept IDs
1663745, 1663747
Application numbers
NDA207917

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube